NCT01889277View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Diabetic Nephropathy
Interventions
DRUG

MT-3995-Low

DRUG

MT-3995-High

DRUG

Placebo

Trial Locations (1)

Unknown

Koukan Hospital, Kawasaki

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY